全文获取类型
收费全文 | 112899篇 |
免费 | 8558篇 |
国内免费 | 3630篇 |
专业分类
耳鼻咽喉 | 738篇 |
儿科学 | 1498篇 |
妇产科学 | 1234篇 |
基础医学 | 16385篇 |
口腔科学 | 1893篇 |
临床医学 | 7788篇 |
内科学 | 13509篇 |
皮肤病学 | 2286篇 |
神经病学 | 7803篇 |
特种医学 | 2090篇 |
外国民族医学 | 23篇 |
外科学 | 9293篇 |
综合类 | 14933篇 |
现状与发展 | 11篇 |
预防医学 | 6729篇 |
眼科学 | 1128篇 |
药学 | 18493篇 |
11篇 | |
中国医学 | 4891篇 |
肿瘤学 | 14351篇 |
出版年
2023年 | 1366篇 |
2022年 | 2075篇 |
2021年 | 3709篇 |
2020年 | 2879篇 |
2019年 | 5546篇 |
2018年 | 4965篇 |
2017年 | 3897篇 |
2016年 | 3091篇 |
2015年 | 4024篇 |
2014年 | 6627篇 |
2013年 | 6638篇 |
2012年 | 5535篇 |
2011年 | 6483篇 |
2010年 | 5739篇 |
2009年 | 6218篇 |
2008年 | 5395篇 |
2007年 | 6139篇 |
2006年 | 5524篇 |
2005年 | 4659篇 |
2004年 | 3638篇 |
2003年 | 3561篇 |
2002年 | 2832篇 |
2001年 | 2434篇 |
2000年 | 2316篇 |
1999年 | 1868篇 |
1998年 | 1754篇 |
1997年 | 1536篇 |
1996年 | 1354篇 |
1995年 | 1187篇 |
1994年 | 943篇 |
1993年 | 799篇 |
1992年 | 708篇 |
1991年 | 621篇 |
1990年 | 493篇 |
1989年 | 461篇 |
1988年 | 390篇 |
1987年 | 401篇 |
1986年 | 405篇 |
1985年 | 926篇 |
1984年 | 1057篇 |
1983年 | 691篇 |
1982年 | 748篇 |
1981年 | 648篇 |
1980年 | 609篇 |
1979年 | 477篇 |
1978年 | 371篇 |
1977年 | 294篇 |
1976年 | 253篇 |
1975年 | 194篇 |
1974年 | 179篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
82.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献83.
目的:比较胶质瘤患者胶质瘤组织和瘤旁组织中miR-147表达水平的差异性,进一步分析miR-147与胶质瘤细胞生物学活性的相关性。方法:通过实时荧光定量PCR检测65例胶质瘤患者瘤组织和瘤旁组织中miR-147的表达水平;采用Lipofectamine 2000转染法转染胶质瘤细胞,分为miR-147 mimics组和NC组,检测两组转染效率;进一步通过CCK-8实验、流式细胞实验和Transwell实验比较两组细胞生物活性。结果:胶质瘤组织中miR-147表达水平显著低于瘤旁组织;与NC组比较,miR-147 mimics组细胞不论是增殖能力还是侵袭能力都明显降低,但是,miR-147 mimics组的细胞凋亡率升高。结论:胶质瘤组织中存在miR-147低表达的现象。miR-147在胶质瘤细胞中表达升高能够抑制细胞的增殖能力、降低其侵袭能力,并促使更多的细胞发生晚期凋亡。miR-147可能在胶质瘤中扮演着抑癌基因的重要角色。 相似文献
84.
《European journal of medical genetics》2020,63(6):103919
Neuronal growth regulator 1 (NEGR1), a member of the immunoglobulin superfamily cell adhesion molecule subgroup IgLON, has been involved in neuronal growth and connectivity. Genetic variants, in or near the NEGR1 locus, have been associated with obesity and, more recently, with learning difficulties, intellectual disability, and psychiatric disorders.Here, we described the only second report of NEGR1 gene disruption in 1p31.1 microdeletion in two patients. Patient 1 is a 14-year-old female with neurological and psychiatric features present also in her family. Patient 2 is a 5-month-old infant showing global hypotonia as unique neurological features till now. This patient also carries 7p22.1 duplication, of paternal origin, that could be responsible for some malformations present in the child.We hypothesize a role of NEGR1 in producing the phenotype of our patients and compare them with other cases previously reported in the literature and DECIPHER database to better identify a possible genotype-phenotype correlation. 相似文献
85.
86.
Fei Xu Ming‐Liang Ye Yu‐Peng Zhang Wen‐Jie Li Meng‐Ting Li Hai‐Zhou Wang Xiao Qiu Yan Xu Jin‐Wen Yin Qian Hu Wan‐Hui Wei Ying Chang Lan Liu Qiu Zhao 《Cancer science》2020,111(5):1528-1541
Resistance to chemotherapy is a major challenge for the treatment of patients with colorectal cancer (CRC). Previous studies have found that microRNAs (miRNAs) play key roles in drug resistance; however, the role of miRNA‐373‐3p (miR‐375‐3p) in CRC remains unclear. The current study aimed to explore the potential function of miR‐375‐3p in 5‐fluorouracil (5‐FU) resistance. MicroRNA‐375‐3p was found to be widely downregulated in human CRC cell lines and tissues and to promote the sensitivity of CRC cells to 5‐FU by inducing colon cancer cell apoptosis and cycle arrest and by inhibiting cell growth, migration, and invasion in vitro. Thymidylate synthase (TYMS) was found to be a direct target of miR‐375‐3p, and TYMS knockdown exerted similar effects as miR‐375‐3p overexpression on the CRC cellular response to 5‐FU. Lipid‐coated calcium carbonate nanoparticles (NPs) were designed to cotransport 5‐FU and miR‐375‐3p into cells efficiently and rapidly and to release the drugs in a weakly acidic tumor microenvironment. The therapeutic effect of combined miR‐375 + 5‐FU/NPs was significantly higher than that of the individual treatments in mouse s.c. xenografts derived from HCT116 cells. Our results suggest that restoring miR‐375‐3p levels could be a future novel therapeutic strategy to enhance chemosensitivity to 5‐FU. 相似文献
87.
In the present study, we investigated the role of miR-122 in hepatocarcinoma progression and explored the
mechanism. In hepatocarcinoma tissues and cells, we used qRT-PCR to validate the miR-122 expression level.
Next, we used colony formation by crystal violet staining assay to compare cell proliferation ability, and we
used scratch test or Transwell assay to compare cell migration or invasion ability. We then conducted bioinformatics or luciferase reporter gene assay to prove the regulation effect of miR-122 on lamin B2 (LMNB2),
and the biological function of LMNB2 was analyzed. We used nude mouse tumorigenicity assay to test the
inhibition effect of miR-122 ASO therapy against hepatocarcinoma. miR-122 was reduced in hepatocarcinoma
tissues compared to the paracarcinoma tissues, which was relatively low or high in hepatocarcinoma cell line
SMMC7721 or Hep3B, and overexpressed miR-122 inhibited proliferation, migration, and invasion in hepatocarcinoma cells. Additionally, some reports showed that LMNB2 was regulated by miR-122, which inhibited
the expression of LMNB2. Moreover, LMNB2 functioned to promote cell proliferation, migration, and invasion. We could achieve the inhibition of hepatocarcinoma using miR-122 therapy through decreasing LMNB2
expression in vivo. Our data indicated that miR-122 could inhibit hepatocellular carcinoma cell progression by
targeting LMNB2 and as a therapeutic target for hepatocarcinoma treatment. 相似文献
88.
《药学学报(英文版)》2020,10(7):1294-1308
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds with therapeutic advantages over single target inhibitors and drug combinations. Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent in vitro and in vivo antitumor potency. Particularly, compound 30a was orally active and possessed excellent in vivo antitumor activity in the HCT116 xenograft model (TGI = 75.2%, 150 mg/kg, p.o.) without significant toxicity, which was more potent than HDAC inhibitor vorinostat, TOP inhibitor evodiamine and their combination. Taken together, this study highlights the therapeutic advantages of evodiamine-based HDAC1/TOP2 dual inhibitors and provides valuable leads for the development of novel multi-targeting antitumor agents. 相似文献
89.
目的 探讨类风湿关节炎患者外周血miR-150-5p、细胞因子信号抑制因子1(suppressor of cytokine signaling 1,SOCS1)mRNA的表达及对类风湿关节炎(Rheumatoid Arthritis,RA)疾病诊断、中医证型判断的意义。方法 纳入符合诊断标准的RA患者57例及健康对照组19例,根据《22个专业95个病种中医诊疗方案》有关RA的中医证候诊断标准,判断RA的中医证型。qPCR检测RA患者及健康对照组miR-150-5p、SOCS1mRNA的相对表达水平,同时检测血常规、肝功能、肾功能等常规指标。双荧光素酶分析方法判断两者是否存在靶向关系。统计分析miR-150-5p、SOCS1 mRNA对RA疾病的诊断意义及其与中医证型的相关性。结果 RA患者外周血miR-150-5p的相对表达水平下调,低于正常人群(t = -19.019,P < 0.05);其表达水平随疾病活动度升高,有下降趋势;患者外周血SOCS1 mRNA的相对表达水平上调,低于正常人群(t = 5.333,P < 0.05);其表达水平随疾病活动度升高,有上升趋势。MiR-150-5p与SOCS1 mRNA有靶向结合关系(P < 0.05)。通过AUC曲线比较,miR-150-5p的相对表达水平区分RA的敏感性及特异性分别为98.1%、92.1%(AUC = 0.972,P < 0.05);SOCS1 mRNA的相对表达水平无法区分RA(AUC = 0.472,P > 0.05)。RA患者中miR-150-5p的相对表达水平低于3.06,RA患者风湿痹阻证、寒湿痹阻证的相对风险分别为8.33、250.00(P < 0.05)。结论 miR-150-5p、SOCS1 mRNA在RA患者中有差异性表达,且有靶向结合关系。miR-150-5p可能是RA的疾病诊断及中医风湿痹阻证、寒湿痹阻证证型诊断的潜在生物标志物。 相似文献
90.
目的:探讨 miR-9 通过靶向 E 盒结合锌指蛋白 2(zinc finger E-box binding homeobox 2,ZEB2)对小细胞肺癌(small cell lung cancer,SCLC)细胞生物学行为的调控作用,分析miR-9在SCLC中的作用及其工作机制。方法:采用qPCR、WB和免疫组化方法检测于2018年2月至2019年11月于河北医科大学第四医院肿瘤内科接受手术治疗的67例SCLC患者癌组织及癌旁组织中ZEB2的表达。采用TargetScan预测miR-9的潜在靶基因并通过双荧光素酶报告基因试验、qPCR和WB法进行验证。CCK-8法、流式细胞术和Transwell实验检测miR-9和ZEB2 过表达对 NCI-H446 的生物学行为影响,WB法检测对细胞中E-cadherin,N-cadherin和Vimentin蛋白表达的影响。利用miR-9过表达NCI-H446细胞构建SCLC裸鼠移植瘤模型,观察miR-9对裸鼠移植瘤生长的影响。结果:SCLC组织中ZEB2的mRNA和蛋白表达水平明显高于癌旁正常组织(P<0.01)。miR-9在ZEB2的3'' UTR上具有潜在的结合位点,与对照组相比,miR-9过表达组NCI-H446细胞中ZEB2的mRNA和蛋白表达水平明显降低(P<0.01),细胞增殖、迁移和侵袭能力均显著下降(P<0.05或P<0.01),促EMT蛋白表达减少,而同时过表达ZEB2能够逆转上述影响。体内实验中,miR-9过表达组移植瘤体积、重量均明显低于对照组(P<0.05或P<0.01)。miR-9组裸鼠肿瘤组织中和ZEB2蛋白的表达均较对照组明显降低(P<0.01)。结论:miR-9通过靶向调控ZEB2从而抑制SCLC细胞的生物学行为以及NCI-H446裸鼠移植瘤的生长。 相似文献